Hyperfine, Inc. (HYPR) , a pioneer in health technology, recently announced promising interim data on the Swoop Portable magnetic resonance (MR) Imaging for acute stroke diagnosis. These findings, presented at the 2024 European Society of Neuroradiology (ESNR) Annual Meeting, underline how the portable ultra-low-field MRI could revolutionize stroke care, particularly in emergency department settings. HYPR's Likely Stock Trend Following the News Following the news, shares of HYPR rose 1.5% at yesterday's clo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ Class A common stock, $0.0001 Par Value Per Share HYPR The Nasdaq Stock Market LLC FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ | --- | --- | --- ...

Hyperfine, Inc. (NASDAQ:HYPR) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Yuan Zhi - B. Riley Operator Good afternoon, and welcome to Hyperfine’s Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to tu ...

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.14, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Hyperfine, which belongs to the Zacks Medical - ...

Hyperfine (HYPR) recently announced the receipt of FDA 510(k) clearance for the ninth generation of its AIpowered Swoop system software. It is the world's first FDA-cleared portable magnetic resonance (MR) brain imaging system. The advanced software significantly reduces scan times across multiple MR sequences without sacrificing image quality. With the launch of the ninth-generation AI-powered software, Hyperfine keeps expanding the Swoop system's clinical utility and workflow fit. In acute care settings, ...

Another Notable Development Hyperfine's track record of securing international approvals supports its expansion into global markets. Along with the latest expansion in the European market, the company also announced a distribution agreement to develop Asian markets. Estimates for Medpace's 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have soared 73.3% in the past year compared with the industry's 5.2% growth. With the recent addition of distributors and the previousl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ Commission File Number: 001-39949 Hyperfine, Inc. (Exact name of registrant as specified in its cha ...

Hyperfine, Inc. (NASDAQ:HYPR) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Operator Good afternoon, and welcome to the Hyperfine's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will be facilitating ...

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.15, delivering a surprise of 11.76%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Hyperfine, which belongs to the Zacks M ...

Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2024 Financial Results GUILFORD, Connecticut, May 13, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales ...